BindingDB logo
myBDB logout

73 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
27810438 49 Improved binding affinities of pyrrolidine derivatives as Mcl-1 inhibitors by modifying amino acid side chains.EBI Shandong University
27712939 63 Design, synthesis, and activity evaluation of selective inhibitors of anti-apoptotic Bcl-2 proteins: The effects on the selectivity of the P1 pockets in the active sites.EBI China Pharmaceutical University
27353532 6 Structural modification of luteolin from Flos Chrysanthemi leads to increased tumor cell growth inhibitory activity.EBI Second Military Medical University
26988306 12 Selective inhibitors of Bcl-2 and Bcl-xL: Balancing antitumor activity with on-target toxicity.EBI AstraZeneca
26878343 114 Discovery of 2-Indole-acylsulfonamide Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods.EBI Vanderbilt University School of Medicine
26764190 4 Peptide-based inhibitors of protein-protein interactions.EBI Wroclaw University of Technology
26558516 39 Design, synthesis and preliminary bioactivity studies of imidazolidine-2,4-dione derivatives as Bcl-2 inhibitors.EBI Shandong University
26421995 49 Design, synthesis and biological evaluation of 3-aryl-rhodanine benzoic acids as anti-apoptotic protein Bcl-2 inhibitors.EBI Shandong University
25844895 61 Discovery of tricyclic indoles that potently inhibit Mcl-1 using fragment-based methods and structure-based design.EBI Vanderbilt University School of Medicine
25679114 48 Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity.EBI AbbVie Inc.
25668341 50 Structure-based lead optimization and biological evaluation of BAX direct activators as novel potential anticancer agents.EBI Universit£ di Napoli"Federico II"
25818766 45 Design, synthesis and preliminary bioactivity studies of 2-thioxo-4-thiazolidinone derivatives as Bcl-2 inhibitors.EBI Shandong University
25797160 23 A combination of in silico and SAR studies to identify binding hot spots of Bcl-xL inhibitors.EBI Bioprojet-Biotech
24881567 73 Towards the next generation of dual Bcl-2/Bcl-xL inhibitors.EBI AstraZeneca
25452002 9 A simple and widely applicable hit validation strategy for protein-protein interaction inhibitors based on a quantitative ligand displacement assay.EBI Takeda Pharmaceutical Company Limited
25313317 51 Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity.EBI AbbVie, Inc.
24901800 12 Endiandric acid analogues from Beilschmiedia ferruginea as dual inhibitors of Bcl-xL/Bak and Mcl-1/Bid interactions.EBI Institut de Chimie des Substances Naturelles (ICSN)
24944740 37 Structure-Guided Rescaffolding of Selective Antagonists of BCL-XL.EBI Genentech
24749893 123 3-Substituted-N-(4-hydroxynaphthalen-1-yl)arylsulfonamides as a novel class of selective Mcl-1 inhibitors: structure-based design, synthesis, SAR, and biological evaluation.EBI University of Michigan Medical School
23993674 9 Hydroxyquinoline-derived compounds and analoguing of selective Mcl-1 inhibitors using a functional biomarker.EBI Eutropics Pharmaceuticals
23767404 97 Discovery of potent and selective benzothiazole hydrazone inhibitors of Bcl-XL.EBI The Walter and Eliza Hall Institute of Medical Research
23220642 30 Novel soluble myeloid cell leukemia sequence 1 (Mcl-1) inhibitor (E,E)-2-(benzylaminocarbonyl)-3-styrylacrylonitrile (4g) developed using a fragment-based approach.EBI Dalian University of Technology
23448298 58 A potent and highly efficacious Bcl-2/Bcl-xL inhibitor.EBI University of Michigan
23244564 114 Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design.EBI Vanderbilt University School of Medicine
23206987 66 3-Thiomorpholin-8-oxo-8H-acenaphtho [1,2-b] pyrrole-9-carbonitrile (S1) derivatives as pan-Bcl-2-inhibitors of Bcl-2, Bcl-xL and Mcl-1.EBI Dalian University of Technology
20728251 42 3D-QSAR pharmacophore modeling and in silico screening of new Bcl-xl inhibitors.EBI Universit£ degli Studi di Palermo
23047228 24 Synthesis and biological activities of polyquinoline derivatives: new Bcl-2 family protein modulators.EBI Clermont Universit£
22747598 33 Structure-based design of potent Bcl-2/Bcl-xL inhibitors with strong in vivo antitumor activity.EBI University of Michigan
22448988 77 Design of Bcl-2 and Bcl-xL inhibitors with subnanomolar binding affinities based upon a new scaffold.EBI University of Michigan
22608961 46 Identification of a phenylacylsulfonamide series of dual Bcl-2/Bcl-xL antagonists.EBI Bristol-Myers Squibb Research
22608393 64 Pyrazole and pyrimidine phenylacylsulfonamides as dual Bcl-2/Bcl-xL antagonists.EBI Bristol-Myers Squibb Research
22230199 12 Unbiased binding assays for discovering small-molecule probes and drugs.EBI Broad Institute of Harvard and MIT
20443627 26 BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins.EBI Sanford-Burnham Medical Research Institute
19743858 6 Structure-activity relationship and molecular mechanisms of ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4h-chromene-3-carboxylate (sha 14-1) and its analogues.EBI University of Minnesota
15214773 76 Fragment-based drug discovery.EBI Sunesis Pharmaceuticals Inc.
13678404 7 Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins.EBI Institute
22172701 40 Design, synthesis, and activity evaluation of broad-spectrum small-molecule inhibitors of anti-apoptotic Bcl-2 family proteins: characteristics of broad-spectrum protein binding and its effects on anti-tumor activity.EBI Second Military Medical University
21807512 29 Biochemical and pharmacological profiling of the pro-survival protein Bcl-xL.EBI University of Washington
21797225 70 SAR by interligand nuclear overhauser effects (ILOEs) based discovery of acylsulfonamide compounds active against Bcl-x(L) and Mcl-1.EBI Sanford-Burnham Medical Research Institute
21366295 40 Quinazoline sulfonamides as dual binders of the proteins B-cell lymphoma 2 and B-cell lymphoma extra long with potent proapoptotic cell-based activity.EBI The Walter and Eliza Hall Institute of Medical Research
21300543 3 Anti-tumor pyrimidinylpiperazines bind to the prosurvival Bcl-2 protein family member Bcl-XL.EBI University of the Pacific
21033669 96 Synthesis and biological evaluation of Apogossypolone derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins.EBI Sanford-Burnham Medical Research Institute
20925433 21 Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.EBI Aristotle University of Thessaloniki
20870405 31 Discovery of a potent and selective Bcl-2 inhibitor using SAR by NMR.EBI Abbott Laboratories
20481544 3 Rearranged diterpenoids from the biotransformation of ent-trachyloban-18-oic acid by Rhizopus arrhizus.EBI Centre de Recherche de Gif
20405848 48 Design, synthesis, and interaction study of quinazoline-2(1H)-thione derivatives as novel potential Bcl-xL inhibitors.EBI Chinese Academy of Sciences
20441222 37 Vaccinia virus virulence factor N1L is a novel promising target for antiviral therapeutic intervention.EBI Institute for Medical Research
20192224 2 Fragment-based deconstruction of Bcl-xL inhibitors.EBI Universite de Lyon
20158203 12 Structural insights into the design of small molecule inhibitors that selectively antagonize Mcl-1.EBI Institute of Chemical and Engineering Sciences
19572612 14 Cytotoxic pentacyclic triterpenoids from Combretum sundaicum and Lantana camara as inhibitors of Bcl-xL/BakBH3 domain peptide interaction.EBI CNRS
19161318 2 A Dimeric sesquiterpenoid from a Malaysian Meiogyne as a new inhibitor of Bcl-xL/BakBH3 domain peptide interaction.EBI CNRS
18845435 11 Interaction of kendomycin and semi-synthetic analogues with the anti-apoptotic protein Bcl-xl.EBI MerLion Pharmaceuticals Pte Ltd
19329314 32 Diversity-oriented synthesis of a cytisine-inspired pyridone library leading to the discovery of novel inhibitors of Bcl-2.EBI Infinity Pharmaceuticals, Inc.
17692431 48 Structure-activity relationships of Bak derived peptides: affinity and specificity modulations by amino acid replacement.EBI INSERM
17181155 23 Structure-activity relationship studies of ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA 14-1), an antagonist for antiapoptotic Bcl-2 proteins to overcome drug resistance in cancer.EBI University of Minnesota
17034116 28 Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins.EBI University of Michigan
16451081 132 Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo.EBI Abbott Laboratories
15006365 15 Terephthalamide derivatives as mimetics of the helical region of Bak peptide target Bcl-xL protein.EBI Yale University
19555126 38 Apogossypol derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins.BDB Burnham Institute for Medical Research
16028929 17 Terphenyl-Based Bak BH3 alpha-helical proteomimetics as low-molecular-weight antagonists of Bcl-xL.BDB Yale University
15826183 33 Terephthalamide derivatives as mimetics of helical peptides: disruption of the Bcl-x(L)/Bak interaction.BDB Yale University
18925736 19 Structure-activity relationship studies of phenanthridine-based Bcl-XL inhibitors.BDB A*STAR
17636950 41 Design, synthesis, and biological evaluation of Plasmodium falciparum lactate dehydrogenase inhibitors.BDB University of Mississippi
17256834 104 Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.BDB Abbott Laboratories